Exciting news for eczema treatment! The FDA has approved #Lebrikizumab, a new IL-13 inhibitor, for moderate to severe #AtopicDermatitis in adults and children 12+ years. okt.to/mctb0e #EczemaRelief #FDAApproval #DermatologyNews #SkincareInnovation #EczemaCare

🧵 FDA Approves Lilly's Ebglyss for Moderate-to-Severe Atopic Dermatitis #Ebglyss #AtopicDermatitis #Eczema #FdaApproval #EliLilly #Lebrikizumab #BiologicTreatment

Leigh Ann Pansch, MSN, FNP-BC, DCNP, Clinical Director of Education at DOCS Dermatology in Cincinnati, shares her enthusiasm about the recent approval of #lebrikizumab-lbkz (Ebglyss, Lilly) for adults and children aged 12 and older with moderate-severe AD. jdnppa.com/introducing-le…

Dr. Andrew Alexis discusses preliminary study results showing that newly U.S. FDA-approved biologic, #lebrikizumab-lbkz (Ebglyss, Lilly), improves post-inflammatory #hyperpigmentation secondary to AD in people with darker skin tones. thedermdigest.com/newly-approved…

When topical steroids aren’t enough to treat #eczema, biologic meds are another choice but they’re dosed as every-other-week injections. FDA approval of Eli Lilly and Company's #lebrikizumab, branded #Ebglyss, introduces an option with once-monthly dosing. medcitynews.com/2024/09/eli-li… $LLY

The indication is supported by trial data showing three-fourths of successfully treated patients maintained clear #skin through 1 year of a #lebrikizumab regimen. More details from the #FDA: contemporarypediatrics.com/view/fda-appro…

#FDA has approved the targeted interleukin (IL)-13 inhibitor #lebrikizumab for the treatment of adults and children age 12 years and older who have moderate-to-severe #AD that is not well controlled, despite treatment with topical prescription therapies. medscape.com/viewarticle/fd…

🚨 NEW TODAY: The US FDA has approved Eli Lilly and Company's #lebrikizumab-lbkz (Ebglyss) for children and adults aged 12 years and older with moderate to severe #atopicdermatitis. #dermtwitter dermatologytimes.com/view/fda-appro…

📈 JUST PUBLISHED: New phase 3 studies show #lebrikizumab significantly improves symptoms and quality of life in atopic dermatitis patients. Read more: bit.ly/47gnrMV #AtopicDermatitis #DermatologyNews

Similar changes in clinical signs, symptoms, pruritus, and quality of life were observed with #lebrikizumab vs #dupilumab among patients with #atopicdermatitis. ⬇️ brnw.ch/21wMnWs

Sustained improvement in #pruritus and #sleep measures were reported among patients with #atopicdermatitis who received #lebrikizumab treatment for 52 weeks, irrespective of the frequency at which patients received the therapy. ⬇️ brnw.ch/21wLTid

Vaccination with 2 nonlive #vaccines among patients with #atopicdermatitis receiving #lebrikizumab did not negatively impact seroresponse or treatment efficacy. 💉 brnw.ch/21wLRUm

Clinically meaningful and sustained improvements in quality of life, and #mentalhealth scores were observed among patients with moderate to severe #atopicdermatitis after 16 weeks of treatment with #lebrikizumab. ⬇️ brnw.ch/21wLP1u

This analysis aimed to illustrate the response trajectories of individual patients treated with #lebrikizumab and the proportions of patients who demonstrated a stable response with no or minimal fluctuation of efficacy from Week 16 to 52 link.springer.com/article/10.100… #AtopicDermatitis

UK health authority recommends Ebglyss ( #lebrikizumab ) an interleukin-13 inhibitor indicated for #atopic #dermatitis treatment in England. healio.com/news/dermatolo…

Authors report the results of a #phase3, 16-week, randomized, double-blind, placebo-controlled, parallel-group study to assess the impact of #lebrikizumab on responses to two non-live vaccines in adult patients with moderate-to-severe #AtopicDermatitis: link.springer.com/article/10.100…

Inhibitors of the IL-13 pathway, such as #dupilumab (dual IL-4/IL-13 inhibitor), #tralokinumab and #lebrikizumab (pure IL-13 inhibitors), were developed to treat atopic diseases including atopic #dermatitis, chronic #rhinosinusitis and #asthma

In this latest study, authors we assess the impact of #lebrikizumab on #QualityOfLife and #MentalHealth after 16 weeks of treatment in patients with moderate-to-severe #AtopicDermatitis: link.springer.com/article/10.100…

Health Canada Authorizes Lilly's #Ebglyss™ (#lebrikizumab) for the Treatment of Moderate-to-Severe #Atopic #Dermatitis in Adults and Adolescents 12 Years and Older. newswire.ca/news-releases/…

Researchers unveil a novel efficacy index for assessing long-term outcomes in #AtopicDermatitis treatments. #Lebrikizumab leads with impressive results compared to #tralokinumab and #dupilumab. okt.to/K57c1x #DermatologyResearch #SkinHealth #EfficacyIndex #DermTwitter